JP2013199488A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013199488A5 JP2013199488A5 JP2013121984A JP2013121984A JP2013199488A5 JP 2013199488 A5 JP2013199488 A5 JP 2013199488A5 JP 2013121984 A JP2013121984 A JP 2013121984A JP 2013121984 A JP2013121984 A JP 2013121984A JP 2013199488 A5 JP2013199488 A5 JP 2013199488A5
- Authority
- JP
- Japan
- Prior art keywords
- tpr
- disintegrating tablet
- orally disintegrating
- beads
- tablet composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011324 bead Substances 0.000 claims 26
- 239000000203 mixture Substances 0.000 claims 22
- 239000006191 orally-disintegrating tablet Substances 0.000 claims 22
- 229920000642 polymer Polymers 0.000 claims 18
- 239000008186 active pharmaceutical agent Substances 0.000 claims 17
- 239000011248 coating agent Substances 0.000 claims 14
- 238000000576 coating method Methods 0.000 claims 14
- 239000007962 solid dispersion Substances 0.000 claims 14
- 230000002708 enhancing effect Effects 0.000 claims 9
- 239000002245 particle Substances 0.000 claims 9
- 239000002702 enteric coating Substances 0.000 claims 7
- 238000009505 enteric coating Methods 0.000 claims 7
- 229920001577 copolymer Polymers 0.000 claims 6
- 239000002904 solvent Substances 0.000 claims 6
- 229920003176 water-insoluble polymer Polymers 0.000 claims 6
- 239000008187 granular material Substances 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 150000005846 sugar alcohols Chemical class 0.000 claims 3
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 150000001720 carbohydrates Chemical class 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 2
- ZDXUKAKRHYTAKV-UHFFFAOYSA-N lercanidipine Chemical group COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZDXUKAKRHYTAKV-UHFFFAOYSA-N 0.000 claims 2
- 229960004294 lercanidipine Drugs 0.000 claims 2
- 230000000873 masking effect Effects 0.000 claims 2
- -1 opioid agonists Substances 0.000 claims 2
- 150000007524 organic acids Chemical class 0.000 claims 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229940127450 Opioid Agonists Drugs 0.000 claims 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000001088 anti-asthma Effects 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 230000003474 anti-emetic effect Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 230000000648 anti-parkinson Effects 0.000 claims 1
- 230000003356 anti-rheumatic effect Effects 0.000 claims 1
- 239000000924 antiasthmatic agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002111 antiemetic agent Substances 0.000 claims 1
- 229940125683 antiemetic agent Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 239000000939 antiparkinson agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 229920002301 cellulose acetate Polymers 0.000 claims 1
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960003120 clonazepam Drugs 0.000 claims 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 claims 1
- 229940097362 cyclodextrins Drugs 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 239000004503 fine granule Substances 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000004083 gastrointestinal agent Substances 0.000 claims 1
- 229940127227 gastrointestinal drug Drugs 0.000 claims 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 229960003162 iloperidone Drugs 0.000 claims 1
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims 1
- 125000005395 methacrylic acid group Chemical group 0.000 claims 1
- 229920000609 methyl cellulose Polymers 0.000 claims 1
- 239000001923 methylcellulose Substances 0.000 claims 1
- 235000010981 methylcellulose Nutrition 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 239000003887 narcotic antagonist Substances 0.000 claims 1
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 claims 1
- 229960002497 nicorandil Drugs 0.000 claims 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims 1
- 229960001597 nifedipine Drugs 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 239000004014 plasticizer Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920002689 polyvinyl acetate Polymers 0.000 claims 1
- 239000011118 polyvinyl acetate Substances 0.000 claims 1
- 125000001453 quaternary ammonium group Chemical group 0.000 claims 1
- 229940125706 skeletal muscle relaxant agent Drugs 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 239000007916 tablet composition Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84176006P | 2006-08-31 | 2006-08-31 | |
| US84189306P | 2006-08-31 | 2006-08-31 | |
| US60/841,893 | 2006-08-31 | ||
| US60/841,760 | 2006-08-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009526896A Division JP5513113B2 (ja) | 2006-08-31 | 2007-08-29 | 弱塩基性薬剤の固溶体を含む薬剤送達システム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013199488A JP2013199488A (ja) | 2013-10-03 |
| JP2013199488A5 true JP2013199488A5 (enExample) | 2014-04-17 |
| JP5913207B2 JP5913207B2 (ja) | 2016-04-27 |
Family
ID=39136847
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009526896A Expired - Fee Related JP5513113B2 (ja) | 2006-08-31 | 2007-08-29 | 弱塩基性薬剤の固溶体を含む薬剤送達システム |
| JP2013121984A Active JP5913207B2 (ja) | 2006-08-31 | 2013-06-10 | 弱塩基性薬剤の固溶体を含む薬剤送達システム |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009526896A Expired - Fee Related JP5513113B2 (ja) | 2006-08-31 | 2007-08-29 | 弱塩基性薬剤の固溶体を含む薬剤送達システム |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20080069878A1 (enExample) |
| EP (1) | EP2056792B1 (enExample) |
| JP (2) | JP5513113B2 (enExample) |
| KR (2) | KR101468053B1 (enExample) |
| BR (1) | BRPI0716196A2 (enExample) |
| CA (1) | CA2661683C (enExample) |
| ES (1) | ES2953390T3 (enExample) |
| IL (1) | IL197204A0 (enExample) |
| MX (2) | MX2009002166A (enExample) |
| NZ (1) | NZ575171A (enExample) |
| RU (1) | RU2434630C2 (enExample) |
| WO (1) | WO2008027993A2 (enExample) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8071128B2 (en) | 1996-06-14 | 2011-12-06 | Kyowa Hakko Kirin Co., Ltd. | Intrabuccally rapidly disintegrating tablet and a production method of the tablets |
| US8747895B2 (en) * | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| EP1802285B1 (en) | 2004-10-21 | 2013-02-27 | Aptalis Pharmatech, Inc. | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
| US9161918B2 (en) | 2005-05-02 | 2015-10-20 | Adare Pharmaceuticals, Inc. | Timed, pulsatile release systems |
| US7973025B2 (en) | 2005-05-26 | 2011-07-05 | Neuron Systems, Inc. | Compositions and methods of treating retinal disease |
| US20070087056A1 (en) * | 2005-08-09 | 2007-04-19 | Claudia Guthmann | Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility |
| JP5513113B2 (ja) | 2006-08-31 | 2014-06-04 | アプタリス ファーマテック，インコーポレイテッド | 弱塩基性薬剤の固溶体を含む薬剤送達システム |
| BRPI0821985A2 (pt) * | 2008-01-10 | 2015-06-23 | Evonik Roehm Gmbh | Preparacao farmacêutica ou nutracêutica revestida tendo liberação de substância ativa controlada |
| US9011907B2 (en) * | 2008-01-10 | 2015-04-21 | Evonik Röhm Gmbh | Coated pharmaceutical or nutraceutical preparation with enhanced pulsed active substance release |
| US8133506B2 (en) * | 2008-03-12 | 2012-03-13 | Aptalis Pharmatech, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
| FR2930147B1 (fr) * | 2008-04-18 | 2013-02-08 | Flamel Tech Sa | Forme orale solide dotee d'un double profil de liberation |
| CA2722314C (en) * | 2008-04-29 | 2018-01-02 | Pharnext | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response |
| MX2010012080A (es) * | 2008-05-05 | 2011-04-11 | Univ Winthrop Hospital | Metodo para mejorar el perfil de riesgo cardiovascular de los inhibidores de cox. |
| EP2285219B1 (en) * | 2008-05-08 | 2018-07-18 | Supernus Pharmaceuticals, Inc. | Controlled release formulations of alprazolam |
| FR2938432B1 (fr) * | 2008-11-14 | 2011-05-20 | Debregeas Et Associes Pharma | Nouveau procede de preparation de granules de principes actifs, et granules tels qu'obtenus |
| KR101689688B1 (ko) * | 2008-11-18 | 2016-12-26 | 유씨비 파마, 에스.에이. | ２옥소１피롤리딘 유도체를 포함하는 지연 방출형 제형 |
| DK2358361T3 (en) * | 2008-11-18 | 2016-12-12 | Ucb Biopharma Sprl | DEPOT formulation comprising a 2-oxo-1-pyrrolidine. |
| EP2374460A4 (en) * | 2008-12-12 | 2013-08-21 | Rhein Siegfried Sa De Cv | SILDENAFIL COMPOSITION WITH PULSED RELEASE AND METHOD FOR PRODUCING THIS COMPOSITION |
| AU2009335709A1 (en) | 2008-12-19 | 2011-07-14 | Supernus Pharmaceuticals, Inc. | Method of treatment of aggression |
| US20100172979A1 (en) * | 2008-12-24 | 2010-07-08 | Zhongshui Yu | Controlled-release formulations |
| US20100159009A1 (en) * | 2008-12-24 | 2010-06-24 | Zhongshui Yu | Controlled-release formulations |
| US20120108464A1 (en) * | 2009-01-29 | 2012-05-03 | Sanofi-Aventis | Test systems, methods and uses involving as160 protein |
| WO2010096820A1 (en) * | 2009-02-23 | 2010-08-26 | Eurand, Inc. | Controlled release compositions comprising anti-cholinergic drugs |
| EP2398470A4 (en) * | 2009-02-23 | 2013-03-06 | Aptalis Pharmatech Inc | CONTROLLED RELEASE COMPOSITIONS COMPRISING A PROTON PUMP INHIBITOR |
| RU2016120727A (ru) * | 2009-04-09 | 2018-11-12 | Алкермес Фарма Айэленд Лимитед | Композиция для доставки лекарственных средств |
| EP2478019B1 (de) | 2009-09-17 | 2015-04-01 | Basf Se | Mit wirkstoffhaltigen überzügen beschichtete pellets |
| FR2951378B1 (fr) * | 2009-10-16 | 2012-06-01 | Flamel Tech Sa | Forme pharmaceutique orale solide anti-mesusage et dotee d'un profil specifique de liberation modifiee |
| EP2506835B1 (en) | 2009-11-30 | 2019-06-12 | Adare Pharmaceuticals, Inc. | Compressible-coated pharmaceutical compositions and tablets and methods of manufacture |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| US20130004545A1 (en) | 2009-12-23 | 2013-01-03 | Lupin Limited | Slow release pharmaceutical compositions of iloperidone |
| CN102106807B (zh) * | 2009-12-29 | 2013-03-27 | 上海中西制药有限公司 | 一种固体制剂的制备方法及所得固体制剂 |
| US20110256218A1 (en) * | 2010-01-04 | 2011-10-20 | Eurand, Inc. | Controlled release compositions comprising meclizine or related piperazine derivatives |
| WO2011085181A1 (en) * | 2010-01-08 | 2011-07-14 | Eurand, Inc. | Taste masked topiramate composition and an orally disintegrating tablet comprising the same |
| DE102010005124A1 (de) * | 2010-01-19 | 2012-03-01 | Stada Arzneimittel Ag | Feste pharmazeutische Zusammensetzung umfassend Lercanidipin |
| ES2643497T3 (es) | 2010-03-31 | 2017-11-23 | Supernus Pharmaceuticals, Inc. | Formulaciones estabilizadas de compuestos del SNC |
| WO2011135430A1 (en) * | 2010-04-29 | 2011-11-03 | Lupin Limited | Controlled release pharmaceutical compositions of brivaracetam |
| AU2011256928A1 (en) * | 2010-05-24 | 2012-12-20 | Lupin Limited | Extended release formulation of pramipexole |
| WO2012005359A1 (ja) * | 2010-07-09 | 2012-01-12 | 帝人ファーマ株式会社 | 口腔内崩壊錠剤 |
| US9011912B2 (en) | 2010-10-07 | 2015-04-21 | Abon Pharmaceuticals, Llc | Extended-release oral dosage forms for poorly soluble amine drugs |
| CN102440971A (zh) * | 2010-10-15 | 2012-05-09 | 重庆市力扬医药开发有限公司 | 伊潘立酮口腔崩解片 |
| CN103402497A (zh) | 2010-12-02 | 2013-11-20 | 阿普塔利斯医药科技公司 | 快速分散颗粒、口腔崩解片以及方法 |
| CN102614140B (zh) * | 2011-01-26 | 2015-11-25 | 浙江九洲药物科技有限公司 | 伊潘立酮口崩片及其制备方法 |
| WO2012123963A2 (en) * | 2011-02-24 | 2012-09-20 | Megafine Pharma (P) Ltd. | A process for preparation of iloperidone and amorphous co- precipitate of iloperidone with pharmaceutically acceptable excipient |
| DE102011051308A1 (de) * | 2011-06-24 | 2012-12-27 | Hennig Arzneimittel Gmbh & Co. Kg | Herstellungsverfahren und Arzneiform |
| BR112014003061A2 (pt) | 2011-08-12 | 2017-02-21 | Boehringer Ingelheim Vetmedica Gmbh | composição farmacêutica com sabor mascarado |
| EP2604256B1 (en) * | 2011-12-14 | 2016-04-13 | Hexal AG | Multi layer coatings |
| US11957792B2 (en) * | 2012-04-19 | 2024-04-16 | Glatt Ag | Taste-masked pharmaceutical compositions containing diclofenac |
| CN104640547B (zh) * | 2012-09-19 | 2017-07-11 | 大鹏药品工业株式会社 | 具有改善的溶出度和/或吸收的用于口服的药物组合物 |
| US8999393B1 (en) * | 2013-01-09 | 2015-04-07 | Edgemont Pharmaceuticals Llc | Sustained release formulations of lorazepam |
| CA2898631C (en) | 2013-01-23 | 2023-06-13 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
| AU2014212109B2 (en) | 2013-02-01 | 2018-05-31 | Glialogix, Inc. | Compositions and methods for the treatment of neurodegenerative and other diseases |
| US9339489B2 (en) | 2013-03-15 | 2016-05-17 | Aprecia Pharmaceuticals Company | Rapid disperse dosage form containing levetiracetam |
| ES2688880T3 (es) * | 2013-03-15 | 2018-11-07 | Aprecia Pharmaceuticals LLC | Forma de dosificación de dispersión rápida que contiene levetiracetam |
| JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US10632113B2 (en) | 2014-02-05 | 2020-04-28 | Kashiv Biosciences, Llc | Abuse-resistant drug formulations with built-in overdose protection |
| CA2943024A1 (en) * | 2014-03-18 | 2015-09-24 | Takeda Pharmaceutical Company Limited | Solid dispersion |
| AU2015237721B2 (en) | 2014-03-26 | 2018-04-26 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release coated reservoir solid dosage form |
| WO2016010771A1 (en) | 2014-07-17 | 2016-01-21 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| CN106687119A (zh) * | 2014-07-17 | 2017-05-17 | 杰罗米.申塔格 | 用于器官再生的内源性回肠制动激素途径的激活和相关的组合物、治疗方法、诊断学、和调控系统 |
| GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| CA2996183A1 (en) | 2015-08-21 | 2017-03-02 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| MX395521B (es) | 2016-04-08 | 2025-03-25 | Cereno Scient Ab | Formulaciones farmacéuticas de liberación retardada que comprenden ácido valproico y usos de estas |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| WO2018055615A1 (en) * | 2016-09-22 | 2018-03-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Injectable implants |
| CN110545821A (zh) * | 2017-02-21 | 2019-12-06 | Ico治疗公司 | 两性霉素b的固体口服调配物 |
| CN111356451A (zh) | 2017-10-10 | 2020-06-30 | 奥尔德拉医疗公司 | 炎性病症的治疗 |
| EP3826609A4 (en) * | 2018-02-21 | 2022-01-12 | Blaesi, Aron H. | Expanding structured dosage form |
| CN112714762A (zh) | 2018-08-06 | 2021-04-27 | 奥尔德拉医疗公司 | 多晶型化合物及其用途 |
| EP3813831B1 (en) * | 2018-09-21 | 2023-03-22 | Amneal Complex Products Research LLC | Extended release compositions comprising trihexyphenidyl |
| WO2020089826A1 (en) * | 2018-11-02 | 2020-05-07 | Zenvision Pharma Llp | Ready to use intravenous infusion of brivaracetam or salt thereof |
| US10679018B1 (en) | 2019-02-05 | 2020-06-09 | International Business Machines Corporation | Magnetic tracking for medicine management |
| US10824822B2 (en) * | 2019-02-05 | 2020-11-03 | International Business Machines Corporation | Magnetic tracking for medicine management |
| US11786518B2 (en) | 2019-03-26 | 2023-10-17 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
| WO2020223717A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| WO2020223685A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2021231792A1 (en) * | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| CN113350309B (zh) * | 2021-08-09 | 2021-11-12 | 北京五和博澳药业股份有限公司 | 一种难溶性药物渗透泵控释片剂及其制备方法 |
| US11648207B1 (en) * | 2021-12-15 | 2023-05-16 | Intas Pharmaceuticals Ltd. | Extended release pharmaceutical composition of Clozapine |
| US12303604B1 (en) * | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5846019A (ja) * | 1981-09-14 | 1983-03-17 | Kanebo Ltd | 持続性ニフエジピン製剤 |
| JP3158435B2 (ja) * | 1989-10-26 | 2001-04-23 | 日本新薬株式会社 | 徐放性製剤 |
| JP4072597B2 (ja) * | 1994-12-27 | 2008-04-09 | ナムローゼ・フェンノートシャップ・オルガノン | 持続性製剤 |
| JPH08208476A (ja) * | 1995-02-01 | 1996-08-13 | Kanebo Ltd | ニフェジピン含有持続性製剤 |
| AU733032C (en) | 1996-06-14 | 2002-01-03 | Kyowa Hakko Kirin Co., Ltd. | Intraorally rapidly disintegrable tablet |
| CA2348871C (en) * | 1998-11-02 | 2009-04-14 | John G. Devane | Multiparticulate modified release composition |
| JP2000191519A (ja) * | 1998-12-25 | 2000-07-11 | Nippon Kayaku Co Ltd | 薬効成分の不快な官能的性質が隠蔽された速放性粒状物 |
| US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
| US6500454B1 (en) * | 2001-10-04 | 2002-12-31 | Eurand Pharmaceuticals Ltd. | Timed, sustained release systems for propranolol |
| DE10149674A1 (de) * | 2001-10-09 | 2003-04-24 | Apogepha Arzneimittel Gmbh | Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung |
| US6663888B2 (en) * | 2001-12-14 | 2003-12-16 | Eurand Pharmaceuticals Ltd. | Pulsatile release histamine H2 antagonist dosage form |
| JP5062871B2 (ja) * | 2003-05-13 | 2012-10-31 | 東和薬品株式会社 | 苦味を低減した口腔内崩壊錠剤 |
| US20070105912A1 (en) | 2003-12-01 | 2007-05-10 | Per Holm | Pharmaceutical compositions comprising lercanidipine |
| US8545881B2 (en) * | 2004-04-19 | 2013-10-01 | Eurand Pharmaceuticals, Ltd. | Orally disintegrating tablets and methods of manufacture |
| GB0419355D0 (en) | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
| US20060165788A1 (en) * | 2004-09-09 | 2006-07-27 | Wattanaporn Abramowitz | Lercanidipine pH dependent pulsatile release compositions |
| US20060165789A1 (en) * | 2004-09-09 | 2006-07-27 | Forest Laboratories, Inc. | Lercanidipine modified release compositions |
| US8747895B2 (en) * | 2004-09-13 | 2014-06-10 | Aptalis Pharmatech, Inc. | Orally disintegrating tablets of atomoxetine |
| TW200616681A (en) * | 2004-10-05 | 2006-06-01 | Recordati Ireland Ltd | Lercanidipine capsules |
| US9884014B2 (en) | 2004-10-12 | 2018-02-06 | Adare Pharmaceuticals, Inc. | Taste-masked pharmaceutical compositions |
| EP1802285B1 (en) | 2004-10-21 | 2013-02-27 | Aptalis Pharmatech, Inc. | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
| JP5513113B2 (ja) | 2006-08-31 | 2014-06-04 | アプタリス ファーマテック，インコーポレイテッド | 弱塩基性薬剤の固溶体を含む薬剤送達システム |
-
2007
- 2007-08-29 JP JP2009526896A patent/JP5513113B2/ja not_active Expired - Fee Related
- 2007-08-29 KR KR1020097006605A patent/KR101468053B1/ko not_active Expired - Fee Related
- 2007-08-29 BR BRPI0716196-4A2A patent/BRPI0716196A2/pt not_active IP Right Cessation
- 2007-08-29 CA CA2661683A patent/CA2661683C/en active Active
- 2007-08-29 MX MX2009002166A patent/MX2009002166A/es active IP Right Grant
- 2007-08-29 WO PCT/US2007/077153 patent/WO2008027993A2/en not_active Ceased
- 2007-08-29 KR KR1020147023220A patent/KR20140114887A/ko not_active Ceased
- 2007-08-29 US US11/847,219 patent/US20080069878A1/en not_active Abandoned
- 2007-08-29 ES ES07814553T patent/ES2953390T3/es active Active
- 2007-08-29 EP EP07814553.9A patent/EP2056792B1/en active Active
- 2007-08-29 NZ NZ575171A patent/NZ575171A/en not_active IP Right Cessation
- 2007-08-29 MX MX2014009830A patent/MX370905B/es unknown
- 2007-08-29 RU RU2009111588/15A patent/RU2434630C2/ru not_active IP Right Cessation
-
2009
- 2009-02-24 IL IL197204A patent/IL197204A0/en unknown
-
2013
- 2013-06-06 US US13/911,961 patent/US10864166B2/en active Active
- 2013-06-10 JP JP2013121984A patent/JP5913207B2/ja active Active
-
2020
- 2020-11-02 US US17/086,862 patent/US12151028B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013199488A5 (enExample) | ||
| RU2009111588A (ru) | Системы доставки лекарственных средств, включающие в себя твердые растворы слабоосновных лекарственных средств | |
| JP2020059755A5 (enExample) | ||
| JP2012153724A5 (enExample) | ||
| JP5845173B2 (ja) | 非オピオイドおよびオピオイド鎮痛薬の組み合わせを含む口腔内崩壊錠組成物 | |
| JP2017019858A5 (enExample) | ||
| JP5878022B2 (ja) | 抗コリン薬を具える放出制御組成物 | |
| US20170000799A1 (en) | Oral pharmaceutical composition | |
| JP6929407B2 (ja) | 乱用抵抗性医薬組成物 | |
| JP2009502969A5 (enExample) | ||
| PT1830855E (pt) | Formas de apresentação farmacêuticas sólidas, para administração oral, contendo ritaroxaban com libertação modificada | |
| EP2968181A1 (en) | Rapidly dispersible dosage form of topiramate | |
| JP2007119479A5 (enExample) | ||
| US9629808B2 (en) | Sustained-release solid preparation for oral use | |
| US10004691B2 (en) | Orally disintegrable tablet | |
| HK1209337A1 (en) | Medicament-containing hollow particle | |
| JP2012532194A5 (enExample) | ||
| EP4007568A1 (en) | Pharmaceutical composition comprising dabigatran etexilate | |
| JP2005306778A (ja) | 徐放性製剤及びその製造方法 | |
| WO2022074681A1 (en) | Pharmaceutical compositions with enhanced blend uniformity and content uniformity | |
| ES2516693T3 (es) | Esferoides farmacéuticos | |
| JP5070618B2 (ja) | 腸溶性顆粒剤及びその製造方法 | |
| CN105307644A (zh) | 用于减少递送变化性的具有多种剂量单元的美沙拉嗪药物组合物 | |
| WO2013051036A1 (en) | Use of pharmaceutical composition for gastroretentive sustained and pulsatile drug delivery system | |
| JP5919173B2 (ja) | 徐放性塩酸アンブロキソール口腔内崩壊錠 |